KMKatie R. Mollan

Katie R. Mollan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katie R. Mollan has a total of 347 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-Effectiveness of a Blended Learning Training Approach for Health Care Workers Conducting HIV Index Case Testing in Malawi: Secondary Economic Analysis of a Cluster-Randomized Controlled Trial

    by Poonam Rawat, Nora E Rosenberg, Katie R Mollan, Tapiwa A Tembo, Dhrutika Vansia, Jiayu Wang, Mike J Chitani, Maria H Kim, Ireen Chirombo, Caroline Kumbuyo, et al.

    Background: Index case testing (ICT) is an effective strategy for HIV case finding, but implementation in low- and middle-income countries (LMICs) is often limited by cost and logistical challenges. Traditional ICT training—centralized and in-person—is costly, disrupts service delivery, and varies in quality. Objective: This study evaluates the cost-effectiveness of a blended learning (BL) implementation package designed to build health care worker capacity for ICT, combining tablet-guided teaching and practice sessions, phone-based feedback, and tablet-guided continuous quality improvement, compared with standard of care (SOC) training. Methods: The Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness (PRACTICE) cluster-randomized controlled trial included 33 clusters in southern Malawi from May 2022 to September 2023, randomized 2:1 to SOC (n=22) or SOC + BL implementation package (n=11). Our cost-effectiveness analysis, from the health system perspective, used microcosting, time-and-motion assessments, and observed trial outcomes. The decision tree model estimated total program costs, contact testing outcomes, and incremental cost-effectiveness ratios (ICERs) per contact tested and per person diagnosed with HIV across 1 year of implementation. Sensitivity analyses assessed parameter uncertainty, and a scenario analysis modeled a nationwide scale-up under a decentralized, Ministry of Health–led approach. Results: Our model simulated 100,000 index clients eligible for contact elicitation over 1 year across 2 districts (50,000 per arm). The BL implementation package arm yielded 891 additional contacts tested and 54 more HIV diagnoses. The ICERs were US $125 per contact tested and US $2045 per person diagnosed with HIV; excluding training development costs reduced these to US $69 and US $1136, respectively. Nationwide scale-up under a Ministry of Health–led model further reduced ICERs to US $43 per contact tested and US $698 per person diagnosed with HIV. Probabilistic sensitivity analyses showed the BL implementation package was cost-effective in most simulations. Conclusions: The BL implementation package improved ICT delivery and HIV case finding. Scenario analyses suggested that a decentralized, government-led scale-up could substantially reduce costs and may represent an efficient case-finding strategy, particularly in Malawi’s mature epidemic. BL implementation packages provide a scalable, system-integrated, cost-effective approach that could strengthen health care worker capacity across other service delivery areas in low-resource settings. International Registered Report Identifier (IRRID): RR2-10.1136/bmjopen-2023-077706

  • Open Access

    Efficacy of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Secondary Outcomes from the ACT 2 Randomized Controlled Trial

    by Carla J. Chibwesha, Nicholas S. Teodoro, Katie R. Mollan, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Lisa Rahangdale

    Objective: We report secondary histologic and high-risk HPV (hrHPV) outcomes from the Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV (ACT 2) Trial. Methods: We conducted a double-blind Phase 2b feasibility trial of loop electrosurgical excision procedure (LEEP) combined with adjuvant intravaginal 5-fluorouracil (5FU) cream. Women living with HIV (WLWH) and cervical intraepithelial neoplasia (CIN) 2/3 underwent LEEP and were randomly assigned (1:1) to receive 8 doses of 5FU or placebo cream. Our secondary outcomes were (a) regression of cervical disease and (b) clearance of hrHPV. Results: From March 2023 to January 2025, 180 participants underwent LEEP and were randomized to 5FU or placebo cream. Median age was 41 years (IǪR: 35-45), 29% had HPV16, 18% had HPV18/45; 99% of women were virologically suppressed (<200 copies/mL) and median CD4 count was 636 cells/uL (IǪR: 376-873). 172 participants (95.6%) completed follow-up. At week 24, 96.3% (78/81) in the 5FU group and 82.0% (73/89) in the placebo group regressed to CIN1 or normal histology (PD 14.3%, CI 5.3%, 23.3%). Among participants with positive LEEP margins at week 0, 88.0% (22/25) in the 5FU versus 61.3% (19/31) in the placebo group regressed to CIN1 or normal (PD 26.7%, CI 5.4%, 48.1%). Genotype-specific hrHPV clearance was similar in both groups (5FU: 58.0%, 40/69; Placebo: 53.8%, 43/80; PD 4.2%, CI −11.7%, 20.2%). Conclusion: Clinical outcomes from our Phase 2b trial demonstrates that intravaginal 5FU post-LEEP may be a beneficial adjuvant treatment for CIN2/3. Clinical Trial Registration: NCT05413811

  • Open Access

    Cost-Effectiveness of a Blended Learning Training Approach for Health Care Workers Conducting HIV Index Case Testing in Malawi: Secondary Economic Analysis of a Cluster-Randomized Controlled Trial (Preprint)

    by Poonam Rawat, Nora E Rosenberg, Katie R Mollan, Tapiwa A Tembo, Dhrutika Vansia, Jiayu Wang, Mike J Chitani, Maria H Kim, Ireen Chirombo, Caroline Kumbuyo, et al.

    BACKGROUND Index case testing (ICT) is an effective strategy for HIV case finding, but implementation in low- and middle-income countries (LMICs) is often limited by cost and logistical challenges. Traditional ICT training—centralized and in-person—is costly, disrupts service delivery, and varies in quality. OBJECTIVE This study evaluates the cost-effectiveness of a blended learning (BL) implementation package designed to build health care worker capacity for ICT, combining tablet-guided teaching and practice sessions, phone-based feedback, and tablet-guided continuous quality improvement, compared with standard of care (SOC) training. METHODS The Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness (PRACTICE) cluster-randomized controlled trial included 33 clusters in southern Malawi from May 2022 to September 2023, randomized 2:1 to SOC (n=22) or SOC + BL implementation package (n=11). Our cost-effectiveness analysis, from the health system perspective, used microcosting, time-and-motion assessments, and observed trial outcomes. The decision tree model estimated total program costs, contact testing outcomes, and incremental cost-effectiveness ratios (ICERs) per contact tested and per person diagnosed with HIV across 1 year of implementation. Sensitivity analyses assessed parameter uncertainty, and a scenario analysis modeled a nationwide scale-up under a decentralized, Ministry of Health–led approach. RESULTS Our model simulated 100,000 index clients eligible for contact elicitation over 1 year across 2 districts (50,000 per arm). The BL implementation package arm yielded 891 additional contacts tested and 54 more HIV diagnoses. The ICERs were US $125 per contact tested and US $2045 per person diagnosed with HIV; excluding training development costs reduced these to US $69 and US $1136, respectively. Nationwide scale-up under a Ministry of Health–led model further reduced ICERs to US $43 per contact tested and US $698 per person diagnosed with HIV. Probabilistic sensitivity analyses showed the BL implementation package was cost-effective in most simulations. CONCLUSIONS The BL implementation package improved ICT delivery and HIV case finding. Scenario analyses suggested that a decentralized, government-led scale-up could substantially reduce costs and may represent an efficient case-finding strategy, particularly in Malawi’s mature epidemic. BL implementation packages provide a scalable, system-integrated, cost-effective approach that could strengthen health care worker capacity across other service delivery areas in low-resource settings. INTERNATIONAL REGISTERED REPORT RR2-10.1136/bmjopen-2023-077706

  • Open Access

    Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among Women Living with HIV in South Africa: Primary Outcomes from the ACT 2 Randomized Trial

    by Nicholas S. Teodoro, Katie R. Mollan, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Melissa A. Mischell, Lisa Rahangdale, et al.

    Objective: Determine acceptability and feasibility of loop electrosurgical excision procedure (LEEP) combined with adjuvant intravaginal 5-fluorouracil (5FU) for treatment of cervical intraepithelial neoplasia grade 2/3 (CIN2/3) in women living with HIV (WLWH). Design: Double-blind, randomized, placebo-controlled Phase 2b feasibility trial. Setting: Public-sector hospital in Johannesburg, South Africa. Population: 180 WLWH aged 18+ years with CIN2/3 confirmed by LEEP and on antiretroviral therapy for ≥60 days. Methods: Participants underwent LEEP and were randomly assigned (1:1) to receive 8 doses of adjuvant 5FU or placebo cream every other week and followed for 24 weeks. Main Outcome Measures: The primary outcomes were acceptability and feasibility (adherence, retention, safety, tolerability). Results: Between March 2023 and January 2025, we randomized 180 WLWH. Median age was 41 years (interquartile range [IQR]: 35–45), median CD4+ count was 636 cells/mm³ (IQR: 376–873), and 98.9% were virologically suppressed. Acceptability (>94%) and adherence (>91%) were high and comparable between arms. Retention exceeded 92% in both arms, although Week 24 attendance was lower in the 5FU arm (92.2% vs. 98.9%, probability difference [PD] -6.7%, 95% confidence interval [CI] -14.4%, -0.5%). Safety events were mild, more common with 5FU, and primarily reported as Grade 1 or 2 cervical inflammation (49.2% vs. 26.7%, risk difference [RD] 22.5%, 95% CI 8.6%, 36.4%). One Grade 3 adverse event (an allergic reaction to 5FU) resulted in treatment discontinuation. Conclusions: LEEP plus adjuvant intravaginal 5FU is acceptable and feasible among WLWH in South Africa, supporting progression to a Phase 3 trial. Clinical Trial Registration: NCT05413811. Funding: United States National Institutes of Health (R01CA250850).


  • Open Access

    Serologic Evidence of Hemorrhagic Fever Virus Spillover in Rural Liberia

    by Adam M Schafer, Emmanuel Kerkula, Chanhwa Lee, Alfred Flomo, Amara Fofana, Stanley Kerkula, Thomas Sumo, Alexander Sampson, Samuel Vouh, Fred Flomo, et al.

    Background: Outbreaks of zoonotic emerging infectious diseases, including viral hemorrhagic fevers, are increasing in frequency. Clinical detection remains challenging due to the lack of pathognomonic signs or symptoms and limited access to diagnostics. To better understand the prevalence of prior exposure to viral hemorrhagic fever viruses, serum from community participants in rural Liberia was tested for immunoglobulin G antibodies. Methods: Serum collected from individuals enrolled in the ENABLE study, an observational study of Lassa fever virus incidence and seroprevalence, were analyzed for immunoglobulin G against Ebola virus, Marburg virus, Lassa virus, Rift Valley Fever virus, Crimean-Congo hemorrhagic fever virus, pan-alphavirus, and pan-flavivirus by MAGPIX, a multiplex immune assay. Associations with seropositivity were evaluated using questionnaires that included demographic, animal, and environmental exposure information. Results: Eighty-eight percent of samples from 456 participants tested positive for ≥1 of the viral antibodies with a majority (63%) having antibodies to ≥2 viruses. Seropositivity was highest for Lassa virus (67%) followed by pan-flavivirus (51%), pan-alphavirus (35%), Crimean-Congo hemorrhagic fever virus (24%), Ebolavirus (13%), Rift Valley Fever virus (9%), and Marburg virus (8%). Older age, sex (variable by pathogen), and exposure to cats and rats were associated with seropositivity. Conclusions: These findings demonstrate a significant spillover of filoviruses, bunyaviruses, flaviviruses, and alphaviruses in rural Liberia in contrast with an absence of detected outbreaks. These data support the need for enhanced surveillance and understanding of the ecological and behavioral risk factors for zoonotic spillover events, across a spectrum of disease presentation, given their potential and ongoing threat to global public health.


  • Open Access

    Randomized clinical trial protocol: Acceptability and feasibility of combination treatment for cervical precancer among South African women living with HIV (ACT 2)

    by Carla J. Chibwesha, Katie R. Mollan, Nicholas S. Teodoro, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Lisa Rahangdale


  • Comparative Effectiveness of Levonorgestrel Implant and Depot Medroxyprogesterone Acetate Injectable for Women Living With HIV on Dolutegravir‐Based Antiretroviral Therapy

    by Katie R. Mollan, Brian W. Pence, Daniel Westreich, Agatha Bula, Clara Lemani, John Chapola, Sam Phiri, Jane Chiwoko, Michael G. Hudgens, Lameck Chinula, et al.

    Background: Dolutegravir (DTG)‐based antiretroviral treatment (ART) is broadly prescribed to treat HIV. Effective family planning methods are important for the health of women with HIV (WWH) and their families. For WWH on DTG‐based ART, we compared the typical‐use effectiveness of levonorgestrel (LNG) implant and Depot‐Medroxyprogesterone‐Acetate (DMPA) injectable, two commonly used contraceptive methods. Methods: We analyzed a prospective cohort study conducted in Lilongwe, Malawi from 2017 to 2021. Eligible participants were WWH ages 18–40 years who desired not to get pregnant for ≥ 4 years and chose to initiate either LNG implant or provider‐administered DMPA injectable 0–28 days before study enrollment. Incident pregnancies were measured by urine pregnancy testing and pregnancy diagnoses at study visits every 24 weeks. The parametric g‐formula was applied to estimate the contraceptive effectiveness of LNG implant compared to provider‐administered DMPA injectable, assuming the entire study cohort had used DTG‐based ART throughout. Contraceptive effectiveness was measured during typical, continued use. Results: Overall, 1359 eligible participants were enrolled. At enrollment, the median age was 30 (IQR: 26, 34), and 63% were breastfeeding. With DTG‐based ART, the estimated 96‐week pregnancy risk was 0.5% with LNG implant and 8.9% with DMPA injectable. The estimated 192‐week pregnancy risk was 2.6% with LNG implant and 16.1% with DMPA injectable (risk difference: −13.5 percentage points, 95% CI: −20.1%, −7.5%). Conclusions: For WWH on DTG‐based ART who are seeking reversible contraception, the LNG implant is an effective contraceptive and has substantially higher effectiveness than provider‐administered DMPA injectables.

  • Open Access

    Can digital training improve lay health workers’ knowledge and skills in HIV index case testing? Findings from a cluster randomized trial (Preprint)

    by Tapiwa Tembo, Nora Rosenberg, Katie Mollan, Maria Kim, Sara Rutstein, Angella Mkandawire, Mike Chitani, Caroline Kumbuyo, Duncan Phiri, Mtisunge Mphande, et al.

    Background: Task shifting in low-resource settings requires lay health care workers (HCWs) to provide a variety of health services, such as HIV index case testing, whereby sexual partners and family members of people living with HIV are offered HIV testing. For this, lay HCWs require adequate specialized training. Digital technologies hold promise for training lay HCWs in low-resource settings, but their impacts on improving knowledge, attitudes, and skills are not understood. Objective: This study evaluates the impact of digital training on lay HCWs’ knowledge, attitudes, and skills to provide HIV index case testing. Methods: We recruited lay HCWs from 34 health facilities in Malawi. We conducted a 2-arm cluster randomized controlled trial from 2022 to 2023, evaluating the impact of a digital training approach. Health facilities (clusters) were randomized 1:2 to the enhanced or standard arms. Lay HCWs in both arms received the standard in-person index case testing training. In addition, lay HCWs in the enhanced arm received tablet-guided training. Knowledge acquisition was measured using multiple-choice questionnaires administered before and after training. Attitudinal gains were assessed through a questionnaire with Likert scale responses before and after training. Between-arm mean differences were evaluated using generalized estimating equations. Skills (fidelity to index and contact testing protocols) were measured using 15-item checklists. Fidelity scores were compared between the enhanced and standard arms by estimating mean differences and 95% CIs using generalized estimating equations. Results: We enrolled 306 lay HCWs, with 125 (40.8%) in the enhanced arm and 181 (59.2%) in the standard arm. In the enhanced arm, there was 100% completion of the digital portion, 98% (123/125) completion of the face-to-face tablet-guided portion, and 81% (101/125) to 93% (116/125) completion of quality improvement sessions. Knowledge improved by 4.4% (95% CI 0.7%-8.2%) more in the enhanced arm than in the standard arm ( P =.02). Attitudes toward digital training improved by 4.5% (95% CI 0.3%-7.0%) more in the enhanced arm than in the standard arm ( P =.03). Lay HCWs’ fidelity to index client counseling protocols was 30.5 (95% CI 26.0%-35.0%; P <.001) percentage points higher in the enhanced arm than in the standard arm. Fidelity to contact client counseling protocols was 24.0 (95% CI 20.6%-27.3%; P <.001) percentage points higher in the enhanced arm than in the standard arm. Conclusions: Digital training improved lay HCWs’ knowledge, attitudes, and skills surrounding index case testing counseling. These findings support digital training as a useful strategy for strengthening the capacity of lay HCWs in low-resource contexts.


  • Open Access

    ACT 2 Clinical Trial Design: Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV

    by Carla J. Chibwesha, Katie R. Mollan, Nicholas S. Teodoro, Jessica R. Keys, Chuning Liu, Masangu Mulongo, Sibusisiwe Gumede, Tafadzwa Pasipamire, Mark Faesen, Lisa Rahangdale

    Background: Global efforts to eliminate cervical cancer currently focus on expanding access to HPV vaccination and cervical screening. However, these efforts lack equal investment in treatment of precancerous cervical intraepithelial neoplasia grade 2/3 (CIN2/3), particularly among women with HIV (WWH). This gap leaves a generation of WWH at high risk of persistent/recurrent CIN2/3 and progression to cervical cancer, as standard surgical treatments alone are far less effective in this population. Methods and Design: After randomization, WWH with CIN2/3 (N=180) are randomly allocated to undergo Loop Electrosurgical Excision Procedure (LEEP) followed by self-administration of 8 doses of intravaginal 5% 5-fluorouracil (5FU) or placebo cream (one dose every other week for 16 weeks). Women will be followed for 24 weeks. The primary outcomes are acceptability and feasibility (safety, tolerability, adherence, retention). Secondary outcomes include (a) regression of cervical disease to CIN1 or normal histology and (b) clearance of the hrHPV genotype(s) identified in baseline cervical ThinPrep samples. Discussion: We hypothesize that topical 5FU, a widely available low-cost generic drug, can be repurposed as an adjuvant treatment for CIN2/3 to be self-administered after surgical excision (or ablation) to reduce the risk of persistent/recurrent CIN2/3 and progression to cervical cancer among WWH. In preparation for a large-scale trial to test the effectiveness of combination treatment for CIN2/3 in WWH, we are conducting a Phase 2b feasibility trial of LEEP combined with intravaginal 5FU. Trial Registration: ClinicalTrials.gov , NCT05413811 .

  • Open Access

    Research protocol design and implementation of a hybrid no-touch and low-touch prospective observational study during the COVID-19 public health emergency: the VISION study

    by Becky Straub, Katie R Mollan, Jessica R Keys, Chanhwa Lee, Ronald Swanstrom, Lakshmanane Premkumar, Timothy P Sheahan, Shuntai Zhou, William A Fischer, David A Wohl

    Introduction: The conduct of clinical research is essential during public health emergencies, including COVID-19, to characterise the natural history of the infection to inform case definitions, identify risk factors for severe disease, transmission patterns, short and long-term complications and safe and effective treatments and vaccines. Policies aimed at mitigating transmission of SARS-CoV-2 proved challenging to conduct clinical research. Here, we describe the Vital Status and Outcomes of COVID-19 (VISION) study, a hybrid no-touch and low-touch clinical research protocol following participants recently infected with SARS-CoV-2. Methods and analysis: In this prospective longitudinal no-touch and low-touch observational study of recent SARS-CoV-2 infection, participants are enrolled virtually into a no-touch online primary cohort, which collects clinical information using electronic surveys. Eligible participants are able to additionally enrol into low-touch cohorts that collect biospecimens to characterise viral and immune dynamics. Ethics and dissemination: The VISION study is approved by the UNC Biomedical Institutional Review Board. Virtual enrolment coupled with hybrid no and low-touch data collection reduces barriers to participation in clinical research while allowing for an expansive investigation of the COVID-19 disease course.